The Cooper Companies, Inc.

NasdaqGS:COO Stock Report

Market Cap: US$18.9b

Cooper Companies Valuation

Is COO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COO ($92.39) is trading below our estimate of fair value ($117.89)

Significantly Below Fair Value: COO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COO?

Key metric: As COO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COO. This is calculated by dividing COO's market cap by their current earnings.
What is COO's PE Ratio?
PE Ratio47x
EarningsUS$392.30m
Market CapUS$18.86b

Price to Earnings Ratio vs Peers

How does COO's PE Ratio compare to its peers?

The above table shows the PE ratio for COO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.8x
ALGN Align Technology
36x17.5%US$17.1b
SOLV Solventum
16x6.0%US$11.9b
MMSI Merit Medical Systems
47.2x14.2%US$5.8b
HAE Haemonetics
32x24.3%US$4.1b
COO Cooper Companies
47x19.4%US$18.9b

Price-To-Earnings vs Peers: COO is expensive based on its Price-To-Earnings Ratio (47x) compared to the peer average (32.8x).

Price to Earnings Ratio vs Industry

How does COO's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BDMD Baird Medical Investment Holdings
4.4xn/aUS$54.03m
MHUA Meihua International Medical Technologies
0.8xn/aUS$12.80m
PAVM PAVmed
0.5x-90.0%US$7.47m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
COO 47.0xIndustry Avg. 34.4xNo. of Companies8PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COO is expensive based on its Price-To-Earnings Ratio (47x) compared to the US Medical Equipment industry average (36x).

Price to Earnings Ratio vs Fair Ratio

What is COO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio47x
Fair PE Ratio35.3x

Price-To-Earnings vs Fair Ratio: COO is expensive based on its Price-To-Earnings Ratio (47x) compared to the estimated Fair Price-To-Earnings Ratio (35.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$92.39
US$112.01
+21.2%
10.1%US$125.00US$90.00n/a15
Dec ’25US$104.46
US$114.29
+9.4%
9.2%US$130.00US$92.12n/a14
Nov ’25US$105.85
US$114.29
+8.0%
9.2%US$130.00US$92.12n/a14
Oct ’25US$108.36
US$113.51
+4.8%
8.9%US$130.00US$92.12n/a14
Sep ’25US$105.73
US$114.08
+7.9%
8.0%US$125.00US$95.00n/a13
Aug ’25US$94.20
US$111.46
+18.3%
7.9%US$125.00US$95.00n/a13
Jul ’25US$86.39
US$109.72
+27.0%
8.6%US$125.00US$95.00n/a14
Jun ’25US$94.31
US$108.16
+14.7%
10.0%US$125.00US$86.25n/a15
May ’25US$89.66
US$107.90
+20.3%
9.6%US$125.00US$86.25n/a16
Apr ’25US$99.24
US$107.40
+8.2%
9.5%US$125.00US$86.25n/a16
Mar ’25US$102.19
US$102.81
+0.6%
9.7%US$116.00US$84.30n/a16
Feb ’25US$95.38
US$97.85
+2.6%
8.2%US$110.00US$84.25n/a16
Jan ’25US$94.61
US$96.57
+2.1%
8.2%US$107.50US$84.25n/a16
Dec ’24US$85.27
US$98.10
+15.0%
7.6%US$107.50US$85.75US$104.4615
Nov ’24US$79.23
US$98.25
+24.0%
7.6%US$107.50US$85.75US$105.8515
Oct ’24US$79.50
US$100.57
+26.5%
7.6%US$110.00US$86.25US$108.3614
Sep ’24US$91.17
US$101.16
+11.0%
7.3%US$110.00US$86.25US$105.7314
Aug ’24US$97.50
US$100.38
+2.9%
8.3%US$110.00US$81.25US$94.2014
Jul ’24US$95.86
US$99.50
+3.8%
7.8%US$107.75US$81.25US$86.3914
Jun ’24US$93.55
US$97.43
+4.2%
9.2%US$107.50US$80.00US$94.3113
May ’24US$95.94
US$93.46
-2.6%
8.0%US$107.50US$80.00US$89.6612
Apr ’24US$93.34
US$88.65
-5.0%
8.5%US$97.50US$70.00US$99.2412
Mar ’24US$80.89
US$86.90
+7.4%
9.6%US$96.25US$70.00US$102.1912
Feb ’24US$89.15
US$86.90
-2.5%
9.6%US$96.25US$70.00US$95.3812
Jan ’24US$82.67
US$85.21
+3.1%
8.4%US$93.75US$70.00US$94.6112
Dec ’23US$81.66
US$84.43
+3.4%
8.5%US$92.50US$70.00US$85.2710

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 08:39
End of Day Share Price 2024/12/18 00:00
Earnings2024/10/31
Annual Earnings2024/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

The Cooper Companies, Inc. is covered by 35 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Ishan MajumdarBaptista Research
Joanne WuenschBMO Capital Markets Equity Research